Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $82.8152W HIGH $132.60
Volume
1.12 M
Value Traded
164.65 M
Short % Float
4.97%
-1.17%Week
-7.69%1 Month
-1.26%3 Month
+18.04%6 Month
+15.68%5 Year
+5,081.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
22.86 B
EPS (TTM)
7.95
P/E Ratio
14.18
Ent. Value
18.33 B
Total Shares
202.70 M
Float Shares
200.84 M
Insiders
0.91%
Institutions
103.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
INCY Catalyst Timeline
Dated clinical, regulatory and corporate events for Incyte Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Incyte Corporation
562Total events
27Upcoming
259Tier-1 (high impact)
2019 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseRuxolitinibApprovedCorporate
Specialised Therapeutics expands Incyte partnership to commercialise ruxolitinib cream (Opzelura) in Australia
non-segmental vitiligo; atopic dermatitissource ↗
▲EU ApprovalRuxolitinibApprovedEx-US Regulatory
EC approval of Opzelura for moderate atopic dermatitis in adults
moderate atopic dermatitissource ↗
▼Program DiscontinuationINCB160058DiscontinuedCorporate
Discontinuation of INCB160058 development
▲AcquiredlatarcibartCorporate
Acquisition of Vega Therapeutics including latarcibart
von Willebrand diseasesource ↗
▲PublicationTafasitamabApprovedPresentation
Publication of frontMIND results in The Lancet
DLBCL and HGBLsource ↗
▲Full ResultsVGA039Clinical Data
Datos completos de seguridad y eficacia de dosis múltiples de VGA039 en ISTH 2026
enfermedad de von Willebrandsource ↗
◆Oral PresentationVGA039Presentation
Oral presentation at ISTH 2026 of VGA039 multiple-dose data
von-Willebrand-Syndromsource ↗
▲Oral PresentationVGA039Presentation
Phase 1/2 multidose data for VGA039 presented at ISTH 2026
Von Willebrand Diseasesource ↗
▲Oral PresentationlatarcibartPresentation
ISTH 2026 presentation of Phase 1/2 data for latarcibart
von Willebrand diseasesource ↗
▲PublicationTafasitamabApprovedPresentation
frontMIND results published in The Lancet
DLBCL and HGBLsource ↗
▼Program DiscontinuationINCB160058DiscontinuedCorporate
Discontinuation of INCB160058 development
▲CHMP Positive OpinionRuxolitinibApprovedEx-US Regulatory
Positive CHMP opinion for Opzelura cream in moderate atopic dermatitis
moderate atopic dermatitissource ↗
▲EU ApprovalTafasitamabApprovedEx-US Regulatory
Incyte Japan announces approval of Minjuvi (tafasitamab) in combination with lenalidomide for adults with relapsed or refractory DLBCL
relapsed or refractory diffuse large B-cell lymphoma (DLBCL)source ↗
▲Oral PresentationINCA033989Presentation
Positive Daten zu INCA033989 auf der EHA 2026 präsentiert
Myelofibrose; essenzielle Thrombozythämiesource ↗
◆Oral PresentationTafasitamabApprovedPresentation
Phase 3 frontMIND trial results presented at EHA 2026 plenary session
relapsed/refractory diffuse large B-cell lymphomasource ↗
▲Oral PresentationTafasitamabApprovedPresentation
Results from Phase 3 frontMIND trial of Tafasitamab combination presented at EHA 2026 Congress Plenary
Relapsed/Refractory Diffuse Large B-Cell Lymphomasource ↗
▲Oral PresentationINCA033989Presentation
Positive data presented at EHA 2026 for INCA033989 in essential thrombocythemia
Essential Thrombocythemiasource ↗
▲AcquiredCorporate
Incyte to acquire Vega Therapeutics for $1.25B upfront plus up to $750M in sales milestones
▲Primary Endpoint MetTafasitamabApprovedClinical Data
frontMIND study met primary endpoint: significant improvement in progression-free survival
diffuse large B-cell lymphomasource ↗
◆Topline ReadoutpovorcitinibFiledClinical Data
Topline Phase 3 data for povorcitinib in vitiligo expected mid-2026
nonsegmental vitiligosource ↗
◆Additional DataINCA033989Clinical Data
Updated Phase 1 data for INCA033989 in ET/MF anticipated mid-2026
second-line ET and myelofibrosissource ↗
◆FDA ApprovalRuxolitinibApprovedFDA Decision
Regulatory decision and potential launch for Jakafi XR in U.S. mid-2026
◆FDA ApprovalRuxolitinibApprovedFDA Decision
Expected regulatory decision and potential commercial launch for ruxolitinib XR
▲Oral PresentationTafasitamabApprovedPresentation
EHA 2026 Plenary presentation of frontMIND data
DLBCL and HGBLsource ↗
▲FDA ApprovalTafasitamabApprovedFDA Decision
Japan MHLW approval of Minjuvi for relapsed/refractory DLBCL
relapsed or refractory DLBCLsource ↗
▲Oral PresentationINCA033989Presentation
EHA 2026 presentation of updated Phase 1 data for INCA033989
mutCALR-positive ET and MFsource ↗
◆PublicationTafasitamabApprovedPresentation
Publication of frontMIND results in The Lancet
diffuse large B-cell lymphoma, high-grade B-cell lymphomasource ↗
▲Topline ReadoutTafasitamabApprovedClinical Data
Topline data: tafasitamab combination significantly prolonged progression-free survival, reducing risk of progression or death by 25%
linfoma difuso de células B grandes (LDCBG)source ↗
◆Oral PresentationTafasitamabApprovedPresentation
Full results of Phase 3 frontMIND study of tafasitamab plus lenalidomide and R-CHOP in newly diagnosed DLBCL presented at ASCO 2026
Diffuse Large B-cell Lymphoma (DLBCL)source ↗
▲Full ResultsTafasitamabApprovedClinical Data
Full results presented at ASCO and published in The Lancet
diffuse large B-cell lymphomasource ↗
◆Oral PresentationTafasitamabApprovedPresentation
Presentación oral de resultados completos del estudio frontMIND de fase 3 en ASCO 2026
linfoma difuso de células B grandes (DLBCL)source ↗
◆Full ResultsTafasitamabApprovedClinical Data
Resultados completos del estudio frontMIND de fase 3 presentados en ASCO 2026
linfoma difuso de células B grandes (DLBCL)source ↗
▲Partnership / LicenseCorporate
Strategic collaboration with Edison Scientific to employ Kosmos AI platform
◆Full ResultsRuxolitinibApprovedClinical Data
Datos a largo plazo de 24 semanas del ensayo de fase III TRuE-AD4 de Opzelura en dermatitis atópica moderada
dermatitis atópica moderadasource ↗
◆Full ResultsRuxolitinibApprovedClinical Data
Final 24-week data from Phase 3 TRuE-AD4 trial presented at EADV 2026
moderate atopic dermatitissource ↗
◆Oral PresentationRuxolitinibApprovedPresentation
Presentation at 2026 European Academy of Dermatology and Venereology (EADV)
moderate atopic dermatitissource ↗
▲Long Term DataRuxolitinibApprovedClinical Data
Final 24-week data from Phase 3 TRuE-AD4 of Opzelura cream in adults with moderate AD
moderate atopic dermatitissource ↗
●Poster PresentationRuxolitinibApprovedPresentation
TRuE-AD4 24-week data presented as poster at 2026 EADV Symposium
moderate atopic dermatitissource ↗
▲FDA ApprovalRuxolitinibApprovedFDA Decision
FDA approval of Jakafi XR (ruxolitinib) extended-release tablets for MF, PV, and GVHD
myelofibrosis, polycythemia vera, graft-versus-host diseasesource ↗
▲FDA ApprovalRuxolitinibApprovedFDA Decision
FDA approval of Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease
mielofibrosis, policitemia vera, enfermedad de injerto contra huéspedsource ↗
▲FDA ApprovalRuxolitinibApprovedFDA Decision
FDA approval of Jakafi XR for multiple indications
myelofibrosis, polycythemia vera, acute GVHD, chronic GVHDsource ↗
▲Oral PresentationTafasitamabApprovedPresentation
ASCO 2026 oral presentation of frontMIND data
DLBCL and HGBLsource ↗
Past FDA Catalysts and PDUFA Decisions
How INCY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Povorcitinib (INCB54707) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B75 / 100
Pipeline Score
$10.1B
Pipeline Value
$23.4B
Commercial Value
Fair Value
Valuation Signal
39
Drugs Scored
1.5x
rNPV / MCap
Top 4%
Mid Cap(rank 27 of 657)
Percentile Rank
Incyte Corporation holds a solid B-grade pipeline (75/100), with $11.9B risk-adjusted pipeline value, led by Retifanlimab in Anatomic Stage IV Breast Cancer AJCC v8 (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $5.8B x 4.0 = $23.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| JAKAFI | $3.2B | $3.0B | +6.9% |
| OPZELURA | $988M | $584M | +69.2% |
| NIKTIMVO | $217M | - | - |
| MINJUVI/MONJUVI | $187M | $125M | +49.5% |
| ZYNYZ | $146M | $14M | +941.4% |
| ICLUSIG | $142M | $119M | +18.7% |
| PEMAZYRE | $92M | $84M | +9% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Retifanlimab Monoclonal antibodyMarketedNCT04205812 | Metastatic Squamous Non-Small Cell Lung Cancer | Phase 3 | COMPLETED | 583 | May 28, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every INCY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VGA039 BreakthroughFast TrackOrphan+1 | Von Willebrand disease | Phase 1/2 | 2026-07-14 | significant reduction in bleeding episodesRead More | Samenvatting: Incyte presenteert Fase 1/2 multidosisgegevens voor VGA039 (latarcibart) tijdens ISTH 2026, die aanzienlijke vermindering van bloedingen aantonen bij patiënten met alle types van de ziekte van Von WillebrandRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| CAGNONI PABLO JOfficer (President, Global Head of R&D) | Option | 2,957 186,157 held | $61.76 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INCY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 17.5 % (5.4 %) | 3.49 B | 30.76 M | 0.06% ( 17.92 K) |
INCY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INCY ranks across every disease it competes in
Competitive Position is a premium feature
See how INCY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINCY News
INCY▲ 0%today
Incyte to Report Third Quarter Financial Results
Incyte Corporation is set to announce its financial results for the third quarter of 2026. The announcement will provide insights into the company's performance and financial health during this period. Investors and stakeholders are likely to be keenly awaiting these results to gauge future prospects.
Read more →INCYRiassunto: I dati di Incyte al Congresso dell'Accademia Europea di Dermatologia e Venereologia (EADV) sottolineano l'ampiezza del portafoglio Infiammazione e Autoimmunità di Incyte
Incyte announced that data from its Inflammation and Autoimmunity portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026. The congress is scheduled for September 30 to October 3, 2026, in Vienna, Austria. The breadth of research to be presented underscores the strength of Incyte's portfolio in this area.
Read more →INCYSamenvatting: De gegevens van Incyte op het congres van de Europese Academie voor Dermatologie en Venereologie (EADV) bevestigen de breedte van Incyte's portfolio op het gebied van ontsteking en auto-immuniteit
Incyte announced that it will present data from its inflammation and autoimmunity portfolio at the European Academy of Dermatology and Venereology (EADV) congress in 2026. The event will take place in Vienna, Austria, from September 30 to October 3, 2026. This presentation underscores the strength and breadth of Incyte's research in these therapeutic areas.
Read more →INCYIncyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
Incyte presented data at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, emphasizing the extensive range of its inflammation and autoimmunity portfolio. This event underscores the company's commitment to advancing treatments in these therapeutic areas.
Read more →INCYSpecialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
Specialised Therapeutics has expanded its partnership with Incyte to include the commercialization of ruxolitinib cream (Opzelura®) in Australia. This topical JAK inhibitor is indicated for treating non-segmental vitiligo and atopic dermatitis. ST will handle regulatory submissions and distribution, while Incyte will manage development and manufacturing. The collaboration aims to improve access to this treatment for Australian patients.
Read more →INCYIncyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program
Incyte has announced that MINJUVI (tafasitamab) is now funded in Ontario through the FAST Program for patients with relapsed or refractory follicular lymphoma. This initiative aims to provide quicker access to treatment while formal reimbursement processes are underway. The funding reflects a commitment to enhance treatment options for patients facing this challenging cancer.
Read more →INCYIncyte to Present at Upcoming Investor Conferences
Incyte has announced its participation in several upcoming investor conferences in September 2026. The company will present at the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. These presentations will be available via live webcast and for replay for 30 days, highlighting Incyte's focus on investor engagement.
Read more →INCYGlobal Vitiligo Foundation Applauds Incyte’s “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness
The Global Vitiligo Foundation has endorsed Incyte's 'Moments of Clarity' campaign, which focuses on sharing personal stories of individuals living with nonsegmental vitiligo. This initiative aims to enhance awareness and understanding of the condition, aligning with the foundation's goals of education and community support for affected individuals.
Read more →INCYIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte Corporation has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This rule allows companies to grant stock options or other equity awards to new employees as an inducement to join the company. The announcement was made from Wilmington, Delaware.
Read more →INCYSamenvatting: Opzelura® (ruxolitinib) crème wordt de eerste topische JAK-remmer zonder steroïden die in de Europese Unie is goedgekeurd voor volwassenen met matig ernstige atopische dermatitis
Incyte heeft goedkeuring ontvangen van de Europese Commissie voor Opzelura (ruxolitinib) crème, de eerste topische JAK-remmer zonder steroïden voor volwassenen met matig ernstige atopische dermatitis. Deze goedkeuring biedt een nieuwe behandelingsoptie voor patiënten die onvoldoende baat hebben bij traditionele topische corticosteroïden en calcineurineremmers. Dit is een belangrijke ontwikkeling voor de dermatologische zorg in Europa.
Read more →INCYRiassunto: Opzelura® (ruxolitinib) crema diventa il primo inibitore mirato di JAK privo di steroidi approvato nell'Unione europea per adulti con dermatite atopica moderata
Incyte has received approval from the European Commission for Opzelura (ruxolitinib) cream, marking it as the first steroid-free JAK inhibitor for moderate atopic dermatitis in adults. This treatment is specifically for patients who have not found relief with topical corticosteroids or calcineurin inhibitors. The approval represents a significant advancement in dermatological care for these patients in Europe.
Read more →INCYOpzelura® (Ruxolitinib)-Creme ist der erste steroidfreie topische JAK-Hemmer, der in der Europäischen Union für Erwachsene mit mittelschwerer atopischer Dermatitis zugelassen wurde
Incyte announced that the European Commission has approved Opzelura® (Ruxolitinib) cream for treating moderate atopic dermatitis in adults. This approval is significant as it offers a new, steroid-free treatment option for patients who have not responded adequately to topical corticosteroids and calcineurin inhibitors. The approval is seen as a major milestone for both Incyte and patients in Europe.
Read more →INCYOpzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
Incyte's Opzelura (ruxolitinib) cream has received European Commission approval for treating moderate atopic dermatitis in adults. This marks the first steroid-free topical JAK inhibitor approved in the EU, based on positive Phase 3b TRuE-AD4 study results. The treatment showed significant improvements in clinical signs and symptoms, providing a new option for patients inadequately managed by existing therapies.
Read more →INCY▲ +9.3%on this newsshared move
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
Incyte Corporation has released its financial results for the second quarter of 2026, along with updates regarding its business operations. The report provides insights into the company's performance and strategic direction. Further details on specific financial metrics and business developments were not disclosed in the article.
Read more →INCYSamenvatting: Gegevens van Incyte zullen centraal staan in vier korte mondelinge presentaties tijdens het congres van de European Society for Medical Oncology (ESMO) in 2026, waarin de inspanningen om de behandelresultaten bij moeilijk te behandelen ...
Incyte announced that its data will be highlighted in four oral presentations at the 2026 European Society for Medical Oncology (ESMO) congress. The presentations will focus on efforts to enhance treatment outcomes for challenging cancer cases. This showcases Incyte's ongoing commitment to cancer research and development.
Read more →INCYRiassunto: I dati di Incyte verranno evidenziati in quattro rapide presentazioni orali al Congresso 2026 della European Society for Medical Oncology (ESMO) a supporto dell'impegno per migliorare i risultati nei tumori difficili da curare
Incyte has announced that it will present data from its oncology portfolio at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid. The presentations will include findings from various programs aimed at enhancing treatment outcomes for challenging cancers. The congress is scheduled to take place from October 23 to 27, 2026.
Read more →INCYIncyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
Incyte will showcase data in four rapid oral presentations at the ESMO Congress 2026. This initiative aims to enhance treatment outcomes for patients with difficult-to-treat cancers. The presentations underscore Incyte's dedication to advancing cancer research and improving therapeutic strategies.
Read more →INCYRiassunto: Incyte presenta all'ISTH 2026 i dati di fase 1/2 su dosi multiple di VGA039 (latarcibart) ed evidenzia una sostanziale riduzione del sanguinamento nei pazienti affetti da ogni tipo di malattia di von Willebrand
Incyte has announced positive results from a Phase 1/2 study of VGA039 (latarcibart), an experimental monoclonal antibody targeting protein S in patients with von Willebrand disease (VWD). The study, which included 16 patients, demonstrated a substantial reduction in bleeding episodes. These findings were presented at the ISTH 2026 conference.
Read more →INCYISTH 2026: Incyte präsentiert Daten zur Mehrfachdosierung von VGA039 (Latarcibart) aus einer Phase-1/2-Studie, die eine deutliche Verringerung der Blutungen bei Patienten mit allen Formen des von-Willebrand-Syndroms zeigen
Incyte has released complete safety and efficacy data from a Phase 1/2 study of VGA039 (Latarcibart), a monoclonal antibody targeting Protein S for von Willebrand syndrome (VWS) patients. The study involved 16 patients and demonstrated a notable reduction in bleeding events. These findings are being presented at the 34th Congress of the International Society on Thrombosis.
Read more →INCYSamenvatting: Incyte presenteert Fase 1/2 multidosisgegevens voor VGA039 (latarcibart) tijdens ISTH 2026, die aanzienlijke vermindering van bloedingen aantonen bij patiënten met alle types van de ziekte van Von Willebrand
Incyte has announced positive results from a Phase 1/2 study of VGA039 (latarcibart), a monoclonal antibody targeting protein S, for patients with Von Willebrand disease. The study involved 16 patients and demonstrated a significant reduction in bleeding episodes. This data was presented during the ISTH 2026 conference.
Read more →About Incyte Corporation
Headquarters1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803
BIOPHARMAWATCH ELITE PLUS
Trade the next INCY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime